Talkmed Group Ltd
SGX:5G3
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.355
0.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SGD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Talkmed Group Ltd
Revenue
Talkmed Group Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Talkmed Group Ltd
SGX:5G3
|
Revenue
S$79.1m
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Cordlife Group Ltd
SGX:P8A
|
Revenue
S$36.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
Q & M Dental Group (Singapore) Ltd
SGX:QC7
|
Revenue
S$182.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
Healthway Medical Corporation Ltd
SGX:5NG
|
Revenue
S$160.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
HC Surgical Specialists Ltd
SGX:1B1
|
Revenue
S$18.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
EUDA Health Holdings Ltd
NASDAQ:EUDA
|
Revenue
$3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Talkmed Group Ltd
Glance View
TalkMed Group Ltd. is an investment holding company, which engages in the provision of medical oncology, stem cell transplants, and palliative care services. The firm is a provider of medical oncology and palliative care health care services in Singapore. The firm operates through two segments: Oncology services, and Cellular and gene therapy related products and services. The Oncology services provide specialist doctors and clinical staff to Parkway Cancer Centre (PCC), a division of Parkway Hospitals Singapore Pte. Ltd. for the provision of specialist medical oncology services (consultancy services). The company also provides consultancy services to Thu Cuc International General Hospital (TCH), to enable TCH to operate a medical center for the provision of oncology services in Hanoi, Vietnam. The company also provides consultancy services to the patients in Beijing and Chongqing. Cellular and gene therapy-related products and services include the provision of goods and services related to cellular and gene therapy through its subsidiary, CellVec Pte. Ltd. (CellVec).
See Also
What is Talkmed Group Ltd's Revenue?
Revenue
79.1m
SGD
Based on the financial report for Jun 30, 2024, Talkmed Group Ltd's Revenue amounts to 79.1m SGD.
What is Talkmed Group Ltd's Revenue growth rate?
Revenue CAGR 5Y
2%
Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Talkmed Group Ltd have been 2% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
